



## Harrow Launches VIGAMOX® in the U.S.

July 31, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)--Jul. 31, 2023-- Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. The U.S. commercial rights to VIGAMOX were [purchased](#) by Harrow in January of 2023, and VIGAMOX is the fourth FDA-approved ophthalmic product from that acquisition to have completed the NDA transfer process and become commercially available under the Harrow name.

"Having now completed the NDA transfer of VIGAMOX, we are excited to begin the implementation of the market access, marketing, inventory management, national sales detailing, and other brand-leveraging strategies that we have developed during this transfer period," said Mark L. Baum, Chief Executive Officer of Harrow. "With an exceptional record of safety and efficacy, VIGAMOX is a well-known, reliable, and trusted product by U.S. eyecare professionals, many of whom regard VIGAMOX as the preferred broad-spectrum topical antibiotic to treat patients for bacterial conjunctivitis (sometimes referred to as 'pink eye') as well as many other common bacterial-based infections."

Product orders for VIGAMOX can be made directly through Harrow's dedicated customer service ordering partner, Cardinal's Cordlogistics, which includes a wholesaler distribution system encompassing McKesson and AmerisourceBergen.

### About VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5%:

#### INDICATIONS AND USAGE

VIGAMOX® is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: *Corynebacterium species\**, *Micrococcus luteus\**, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, *Staphylococcus warneri\**, *Streptococcus pneumoniae*, *Streptococcus viridans* group, *Acinetobacter lwoffii\**, *Haemophilus influenzae*, *Haemophilus parainfluenzae\**, and *Chlamydia trachomatis*.

\*Efficacy for this organism was studied in fewer than 10 infections.

#### IMPORTANT SAFETY INFORMATION

##### *Contraindications*

VIGAMOX® is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.

##### *Warnings and Precautions*

- *Hypersensitivity Reactions* – Hypersensitivity and anaphylaxis have been reported with systemic use of moxifloxacin.
- *Prolonged Use* – May result in overgrowth of non-susceptible organisms, including fungi.
- *Avoid Contact Lens Wear* – Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.

##### *Adverse Reactions*

The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1%-6% of patients.

Nonocular adverse events reported at a rate of 1%-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

For complete product information about VIGAMOX®, including important safety information, please visit: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad783689-2b59-448c-b0d6-e8b70cf8b062>.

#### About Harrow

Harrow Health, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit [harrow.com](http://harrow.com).

#### Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on

management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the continued impact of the COVID-19 pandemic and any future health epidemics on our financial condition, liquidity and results of operations; our ability to make commercially available our FDA-approved products and compounded formulations and technologies in a timely manner or at all; market acceptance of the Company's products and challenges related to the marketing of the Company's products; risks related to our pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our products; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and products; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's website at [sec.gov](https://www.sec.gov). Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230731229519/en/): <https://www.businesswire.com/news/home/20230731229519/en/>

**Investors**

Jamie Webb

Director of Communications and Investor Relations

[jwebb@harrowinc.com](mailto:jwebb@harrowinc.com)

615-733-4737

**Media**

Deb Holliday

Holliday Communications, Inc.

[deb@hollidaycommunications.net](mailto:deb@hollidaycommunications.net)

412-877-4519

Source: Harrow Health, Inc.